Vivani says Cortigent-ClearOne deal awaits final regulatory approval
CLRO•Vivani Medical said its deal to make Cortigent a wholly owned subsidiary of ClearOne remains pending final regulatory approval. The parties now expect to complete the transaction shortly after approval, rather than the previously anticipated October 2026 closing.
1. Approval still pending
Vivani Medical said the transaction to make its wholly owned Cortigent subsidiary a wholly owned subsidiary of ClearOne remains pending final regulatory approval. The parties expect to complete it shortly after receiving approval; closing had been anticipated in October 2026. Under the agreement, Cortigent will merge with and into ClearOne's CLRO Merger Sub.
